Oral atovaquone treatment reduced tumour MDSCs and IL-10 in HCC1806, CI66 and 4T1 paclitaxel-resistant (4T1-PR) breast cancer, leading to a reduction in tumour growth by 45%, 70% and 42% respectively. This evidence concerns the gene IL10 and breast carcinoma.